Diabetes Research Paper

New Medications & Methods of Insulin Delivery {text:bookmark-start} {text:bookmark-end} DIABETES RESEARCH PAPER Pharmacology 8 a. m. New Medications & Methods of Insulin Delivery APA 1 Kelsie Marie Hargrays St. Cloud Technical College Abstract {text:bookmark-start} {text:bookmark-end} The research I did was on new medications and methods of insulin delivery. I researched a few new medications that help treat type 1 & 2 diabetes. I also researched about new methods of delivery and found many different methods however, some of them have not yet made it on the market yet.

Another thing I found while conducting my research is that these two topics I have advantages and disadvantages as well which is just another thing that I have included in my research paper. New Medications & Methods of Insulin Delivery Many people around the world of all ages suffer with diabetes every day. The ultimate goal is to cure diabetes and as information technology rapidly improves, diabetes gadgetry is riding its wake. New Diabetes Medication

Currently, there are six types of pills that can help people manage type 1 & 2 diabetes: sulfonylureas, meglitinides, metformin, thiazolidinediones, alpha-glycosidase inhibitors, and DPP-4 inhibitors. There has also been talk about four pharmaceutical classes on the horizon for treating high blood glucose: sodium-glucose co transporter inhibitors, glucokinase activators, glucagon receptor antagonists, and sirtuins. Cycloset was also proved not to increase the risk of heart attack and stroke. Not only that but, Cycloset has also shown to blunt after-meal glucose spikes throughout the day, leading to lower average glucose levels.

Another plus to this medications is the fact that it can be used alone or in combination with other diabetes medications to help improve blood glucose control. These are just some of the advantages to this new medication. In a press release, Brian Schrader, cochairman of S2 Therapeutics, a Bristol, Tenn. , pharmaceutical company licensed by Vero Science to manufacture and sell Cycloset, said the companies intend “to seek a partner to commercialize Cycloset in order to bring this important new therapy to patients as soon as possible. ” New Methods of Insulin Delivery

As insulin continues to be the most potent medicine for people with diabetes needles have already been made to be smaller and less painful than ever before, but scientists continue to work on needle-free delivery systems that would be easier to use and eliminate the need for injections. Of course, the miracle would be an insulin pill. Unfortunately, insulin pills get broken down during the digestion process which means it never makes it into the bloodstream. My research calcified that currently there are no new methods of insulin delivery.

Furthermore there are many methods being engineered as we speak. Some of those methods are Inhaled Insulin, Buccal Insulin (oral spray), Insulin Patch, Artificial Pancreas, and the miracle Insulin Pill. During the clinical study participants were administered insulin through a device similar to an asthma inhaler and most patients needed one to three inhalations for any given dose. Out of those study participants who received inhaled insulin experienced mild to moderate coughing which decreased in severity as the study continued.

The patients on inhaled insulin also reported a higher quality of life and greater satisfaction with their treatment. On the contrary there are some disadvantages to this new delivery system as well. Other A study led by Jay Skyler, MD of the University of Miami and published in the July 2005 issue of the American Diabetes Association journal, Diabetes Care, is the largest study to show that inhaled insulin can safely and effectively replace pre-meal insulin shot in people with type 1 diabetes.

Dr. DeFronzo and his study team write that, “This represents the only demonstration that ADA goals for glycemic control can be achieved in many type 2 diabetic patients using only rapid-acting insulin. ” The authors go on to state that if additional studies confirm these findings, inhaled insulin could become an effective means of controlling blood glucose in patients with type 2 diabetes who cannot achieve adequate blood glucose control with diet and exercise alone. On September 9, 2005 a U.

S. FDA panel voted to advise the FDA to approve Exubera® for use in patients with diabetes. The FDA usually follows the advice of these advisory panels and it is possible that the FDA will approve Exubera® by early 2006. References Gebel, PhD, Erika. American Diabetes Association Home Page – American Diabetes Association. 07 May 2009. Web. 10 Nov. 2009. http://www. diabetes. org/. Link to article: http://www. diabetes. org/assets/pdfs/hot-topics/hot-topics-winter-spring-2006. pdf